MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ
8.63
-0.53
-5.79%
After Hours: 8.63 0 0.00% 16:01 09/29 EDT
OPEN
9.18
PREV CLOSE
9.16
HIGH
9.18
LOW
8.58
VOLUME
183.91K
TURNOVER
0
52 WEEK HIGH
37.00
52 WEEK LOW
8.37
MARKET CAP
1.49B
P/E (TTM)
-5.7629
1D
5D
1M
3M
1Y
5Y
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers
Benzinga · 09/22 08:04
BRIEF-Capital Group Companies' Long Position In H-Shares Of HUTCHMED Falls To 8.99%- HKEX Filing
BRIEF-Capital Group Companies' Long Position In H-Shares Of HUTCHMED Falls To 8.99%- HKEX Filing
Reuters · 09/20 09:20
Nikola, Super Micro Computer And Other Big Losers From Monday
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session.
Benzinga · 09/20 09:12
Groupon, Spectrum Brands, Adobe And Other Big Losers From Thursday
U.S. stocks closed lower with the Nasdaq 100 dropping around 200 points on Thursday. Here is the list of some big stocks recording losses in the previous session.
Benzinga · 09/16 09:25
BRIEF-M&G PLC's Long Position In H-Shares Of HUTCHMED Falls To 5.84% - HKEX Filing
BRIEF-M&G PLC's Long Position In H-Shares Of HUTCHMED Falls To 5.84% - HKEX Filing
Reuters · 09/14 09:21
HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer
Benzinga · 09/08 17:33
Hutchmed Says Colorectal Cancer Drug Increased Overall Survival in Phase 3 Trial
Hutchmed Says Colorectal Cancer Drug Increased Overall Survival in Phase 3 Trial
MT Newswires · 09/08 04:04
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation at the Congress — H...
GlobeNewswire · 08/23 08:30
More
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Webull offers kinds of HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ:HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.